Trimetazidine in conditions other than coronary disease, old drug, new tricks?

Int J Cardiol. 2017 May 1:234:1-6. doi: 10.1016/j.ijcard.2017.02.083. Epub 2017 Feb 24.

Abstract

Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.

Keywords: Contrast-induced nephropathy; Diabetic cardiomyopathy; Myocardial dysfunction induced by anti-cancer drugs; Non-ischemic cardiomyopathy; Sepsis; Trimetazidine.

Publication types

  • Review

MeSH terms

  • Acetyl-CoA C-Acyltransferase / metabolism
  • Antineoplastic Agents / adverse effects*
  • Chemically-Induced Disorders / drug therapy*
  • Chemically-Induced Disorders / etiology
  • Coronary Artery Disease* / drug therapy
  • Coronary Artery Disease* / metabolism
  • Diabetic Cardiomyopathies / drug therapy*
  • Drug Repositioning
  • Humans
  • Kidney Diseases* / chemically induced
  • Kidney Diseases* / drug therapy
  • Mitochondria, Heart / metabolism
  • Trimetazidine / pharmacology*
  • Vasodilator Agents / pharmacology

Substances

  • Antineoplastic Agents
  • Vasodilator Agents
  • Acetyl-CoA C-Acyltransferase
  • Trimetazidine